Veru, Inc. (VERU) Reports Q1 Loss of $0.02/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 First Quarter
February 10, 2021 6:30 AM EST--Q1 FY21 Net Revenues and Gross Profit of $15M and $11M, Respectively, Achieve New Historical Highs for Second Consecutive Quarter--
--Late Clinical Stage Oncology Drug Pipeline Focused on Prostate and Breast Cancers Continues to Advance to Registration Phase 3 Clinical Studies--
--Company Reports Positive Results from Phase 2 Clinical Trial Evaluating VERU-111 for the Treatment of Hospitalized COVID-19 Patients at High Risk for ARDS--
--Company Anticipates Submitting TADFIN New Drug Application with... More
